Can-Fite(US:CANF) Globenewswire·2025-02-05 12:00Core Insights - Can-Fite BioPharma Ltd. is set to present at the BIO CEO & Investor Conference on February 10-11, 2025, in New York City, focusing on its business strategy and clinical milestones [1][2]. Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company specializing in small molecule drugs for oncological and inflammatory diseases, targeting multi-billion-dollar markets [4]. - The company’s lead drug candidate, Namodenoson, is currently in a pivotal Phase III trial for advanced liver cancer and a Phase IIb study for Metabolic Dysfunction-associated Steatohepatitis (MASH) [3][4]. - Another key drug candidate, Piclidenoson, is preparing to enter a pivotal Phase III trial for psoriasis [3][4]. - Can-Fite's third drug candidate, CF602, has shown efficacy in treating erectile dysfunction [4]. Clinical Development - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC treatment by the U.S. FDA [4]. - The company has reported positive topline results for Piclidenoson in a Phase III trial for psoriasis and is expected to advance further [4]. - Can-Fite has conducted clinical studies involving over 1,600 patients, demonstrating an excellent safety profile for its drug candidates [4]. Presentation Details - The presentation at the BIO CEO & Investor Conference will be led by Motti Farbstein, the Chief Executive & Chief Financial Officer, on February 10, 2025, at 3:45 pm EST [6]. - The management team will hold one-on-one meetings with investors and potential partners to discuss the company's future development plans [2].